No Data
Apeloa Pharmaceutical (000739.SZ): Levofloxacin tablets approved to add 0.25g specification.
Gelonghui, November 18th | Apeloa Pharmaceutical (000739.SZ) announced that recently, Apeloa Pharmaceutical Co., Ltd., a holding subsidiary of Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharmaceutical"), received the National Medical Products Administration's issued Levofloxacin Tablets Supplementary Application Approval Notice, approved to increase the 0.25g specification. Levofloxacin tablets are the levorotatory optical isomer of ofloxacin, a third-generation quinolone antibiotic, with a broad spectrum and strong antibacterial properties; it is used to treat mild, moderate, and severe infections in adults (≥18 years old) caused by designated sensitive strains.
Apeloa Pharmaceutical Unit Gets Nod to Market Hepatitis Drug Ingredient
Apeloa Pharmaceutical (000739.SZ): Kangyu Pharmaceutical's meglumine pirepivir active pharmaceutical ingredient approved for marketing.
Geelonghui November 13 | Apeloa Pharmaceuticals (000739.SZ) announced that recently, Zhejiang Apeloa Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Apeloa Pharmaceuticals Limited, received the approval notice for the listing application of sulfamethoxazole prelefuve "Chemical raw material pharmaceutical" issued by the National Medical Products Administration. Sulfamethoxazole prelefuve tablets (trade name: Xin Shumu) is a Class 1 new drug developed by Xi'an Xintong pharmaceutical Research Co., Ltd. (hereinafter referred to as "Xintong Pharmaceutical"), declared and produced by its wholly-owned subsidiary Xi'an Gelan Xintong Pharmaceutical Co., Ltd. (hereinafter referred to as "Gelan Xintong"), used for
Apeloa Pharmaceutical's Adenosylmethionine Butanedisulfonate Tablets Get Nod for Registration
Apeloa Pharmaceutical (000739.SZ): The holding subsidiary Dipyridamole Aspirin Enteric-coated Tablets obtained the pharmaceutical registration certificate.
Gelonghui November 11th | Apeloa Pharmaceutical (000739.SZ) announced that recently, its controlling subsidiary Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharmaceutical") has received the Drug Registration Certificate for Adenosine Disodium Taurocholate Enteric-coated Tablets issued by the National Medical Products Administration (referred to as "NMPA"). Adenosine Disodium Taurocholate Enteric-coated Tablets are suitable for pre-cirrhotic and cirrhotic intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. S-Adenosylmethionine (SAMe) is a natural physiologically active molecule that exists in all tissues and body fluids of the human body, with the liver having the richest content; adenosine.
Apeloa Pharmaceutical Unit Gets China Supplementary Drug Nod for Antidepressant
Is Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?No Data
No Data
